NanoScope Therapeutics Receives Orphan Drug Designation in Saudi Arabia for MCO‑010

NanoScope Therapeutics announced that its lead gene therapy candidate MCO‑010 has received orphan drug designation from the Saudi Food and Drug Authority, a status that offers regulatory incentives to support development for treating inherited retinal diseases. This designation expands the company’s global regulatory leadership in vision restoration and complements existing designations in other regions, enhancing MCO‑010’s development pathway. The recognition may help accelerate access for patients with rare blinding conditions by providing benefits such as protocol assistance, fee reductions, and market exclusivity incentives in Saudi Arabia.